NeuroTrigger
Israel - Tel AvivBiotechnology
Focus: NeuroTrigger is an early-stage Israeli biotech focused on muscle stimulation devices for neurological paralysis indications. Founded in 2024, the company is pre-revenue with a device-based pipeline targeting facial and eye-blinking dysfunction.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About NeuroTrigger
AI assessmentNot HiringNo open roles listed right now. Follow NeuroTrigger to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Neurotrigger Basic. eye blinking stimulator
ParalysisClinical Trials (1)
NCT06069128Evaluate the Usability of the Neuro-trigger Artificial Eye Blinking Stimulation Device in Patients With Paralysis of the Facial Nerve.
N/AHelp build intelligence for NeuroTrigger
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.